PubMed Health⌕ Search

PubMed · 16032263

A reference curve using blood selenium concentration to diagnose selenium deficiency and predict growth responses in lambs.

Abstract

AIMS: To quantify the relationship between blood selenium (Se) concentration and growth response to Se supplementation in lambs, in order to assess the reliability of current reference ranges and to predict the magnitude of likely responses to supplementation. METHODS: Data from 24 Se-supplementation growth-response trials which used the following general protocol were collated and analysed: in each trial, weaned lambs (n=20-30) were allocated randomly to untreated or to Se-supplemented groups. Supplemented groups received 5 mg Se/month as Na2SeO3 in 20 trials, and 1 mg Se/kg liveweight as BaSeO4 in 4 trials. The duration of the trials was 150-196 days, during which time all lambs were weighed every 4-6 weeks and blood samples were taken at various intervals from 10 lambs/group. RESULTS: Among the 24 trials, flock mean blood Se concentrations of the untreated lambs ranged from 32-569 nmol/l, and growth rate of supplemented lambs was -3 to 63 g/day higher than that of untreated lambs. The relationship between blood Se concentration (X) and growth response (Y) was described by the following hyperbolic-decay equation: Y = -2.6 (SE 3.6) + 1850 (SE 230) / X; (R2=0.74). CONCLUSIONS: For Se-deficient lambs, the potential for a growth response to Se supplementation was strongly related to blood Se concentration. Economically significant liveweight gains of 10 g/day were observed when initial blood Se concentrations were 130 nmol/l. CLINICAL RELEVANCE: Blood Se concentrations can be used to diagnose Se deficiency in lambs and to predict the magnitude of likely growth responses to Se supplementation.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

N D Grace, S O Knowles. 2002. A reference curve using blood selenium concentration to diagnose selenium deficiency and predict growth responses in lambs.. https://doi.org/10.1080/00480169.2002.36303

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗